A randomized, double-blind, multicenter study comparing a starting dose of 100 IU or 200 IU of recombinant follicle stimulating hormone (Puregon) in women undergoing controlled ovarian hyperstimulation for IVF treatment.
OBJECTIVE
To compare the efficiency and efficacy of two starting doses of recombinant FSH (follitropin-beta, Puregon) in women undergoing IVF treatment.


METHODS
This prospective, randomized, double-blind, multicentric (N = 6) study included 192 women undergoing IVF using the long protocol of GnRH agonist who received either 100 IU or 200 IU of r-FSH per day. Gonadotropin dose adjustment was allowed after day 4 of stimulation.


RESULTS
The average (SD) number of oocytes retrieved was 10.9 (5.4) and 12.2 (5.6) in the 100 IU and 200 IU group respectively (p = 0.067). The total doses of Puregon administered were 1887 IU and 2559 IU in the 100 IU and 200 IU group respectively. The number of transferable embryos, and the rates of pregnancies, cancelled cycles, miscarriages and adverse events including OHSS were comparable between the two groups.


CONCLUSIONS
Women undergoing IVF have similar outcomes whether recombinant FSH is commenced in a dose of 100 IU or 200 IU for the first 4 days of stimulation.
Tan
Seang Lin
SL
Department of Obstetrics and Gynecology, McGill University, Royal Victoria Hospital, Montreal, Quebec, Canada. seanglin.tan@muhc.mcgill.ca
Child
Timothy J
TJ
Cheung
Anthony P
AP
Fluker
Margo R
MR
Yuzpe
Albert
A
Casper
Robert
R
Leung
Peter
P
Cadesky
Kenneth
K
Davis
Victoria J
VJ
D000328:Adult; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D005307:Fertilization in Vitro; D043373:Follicle Stimulating Hormone, Human / Q000627:therapeutic use*; D006801:Humans; D009865:Oocytes; D010062:Ovulation Induction / Q000379:methods*; D011446:Prospective Studies; D016896:Treatment Outcome
D043373:Follicle Stimulating Hormone, Human